A 32-year-old woman on a combined oral contraceptive pill (30 µg ethinyl estradiol + norgestimate) for the past 3 years presents to the clinic with a 2-month history of breakthrough bleeding. She reports good compliance with pill-taking (same time daily), denies any new medications, and has no gastrointestinal symptoms. Pelvic examination is normal, and cervical cytology is up to date. What is the most appropriate next step in management?

Explanation

## Breakthrough Bleeding: Definition and Approach **Key Point:** Breakthrough bleeding (BTB) is unscheduled vaginal bleeding occurring during the active pill-taking phase. It is common in the first 3–6 months of COCP use but can persist in established users. ## Differential Diagnosis in Established COCP Users | Cause | Frequency | Management | |---|---|---| | **Inadequate progestin** | Most common | Increase progestin or switch to higher-dose pill | | **Inadequate estrogen** | Common | Increase estrogen dose | | **Cervicitis / STI** | Variable | Treat underlying infection | | **Poor compliance** | Variable | Counsel on timing | | **Endometrial pathology** | Rare in young women | Investigate only if red flags present | | **Drug interactions** | Variable | Review concurrent medications | ## Clinical Decision-Making This patient has: - **Established use** (3 years) → not expected first-3-month BTB - **Good compliance** → ruled out - **No GI symptoms** → rules out malabsorption - **Normal pelvic exam** → no acute infection - **Normal cervical cytology** → no cervical pathology **High-Yield:** In the absence of infection, malabsorption, or drug interactions, persistent BTB in an established COCP user is due to **inadequate progestin or estrogen effect**. The standard approach is to **increase the hormone dose**. ## Why Increase Estrogen? Although BTB can result from inadequate progestin, **increasing estrogen is the preferred first-line adjustment** because: 1. Estrogen stabilizes the endometrium and reduces BTB 2. Increasing progestin alone may worsen side effects (mood, libido) 3. A 35 µg pill (from 30 µg) is a modest, safe increase 4. Response is typically seen within 2–3 cycles **Clinical Pearl:** The 30 µg formulation is at the lower end of the estrogen spectrum. A step-up to 35 µg addresses both inadequate estrogen and progestin effects without excessive hormone load. ## Why NOT the Other Options - **Progestin-only pill:** Reserved for estrogen-intolerant patients or those with contraindications to estrogen. Not indicated here. - **Endometrial biopsy:** Unnecessary in a 32-year-old with normal exam and no risk factors for endometrial pathology. BTB alone is not an indication. - **Reassurance alone:** While some BTB resolves spontaneously, 2 months of persistent BTB in an established user warrants intervention. **Mnemonic: STOP BTB** — **S**witch dose, **T**reat infection, **O**ptimize timing, **P**rogestin adjustment, **B**iopsy (only if red flags), **T**ry POP, **B**iopsy (rarely). [cite:NFSG Guidelines on Contraception; Bedsider Clinical Handbook]